US10385027B2 - Triazole derivatives and their use as PDE4 activators - Google Patents

Triazole derivatives and their use as PDE4 activators Download PDF

Info

Publication number
US10385027B2
US10385027B2 US15/559,875 US201615559875A US10385027B2 US 10385027 B2 US10385027 B2 US 10385027B2 US 201615559875 A US201615559875 A US 201615559875A US 10385027 B2 US10385027 B2 US 10385027B2
Authority
US
United States
Prior art keywords
compound
pde4
formula
camp
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/559,875
Other languages
English (en)
Other versions
US20180057466A1 (en
Inventor
Julia Adam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIRONID Ltd
Original Assignee
MIRONID Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIRONID Ltd filed Critical MIRONID Ltd
Assigned to MIRONID LIMITED reassignment MIRONID LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ADAM, JULIA
Publication of US20180057466A1 publication Critical patent/US20180057466A1/en
Application granted granted Critical
Publication of US10385027B2 publication Critical patent/US10385027B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Definitions

  • the present invention relates to compounds of Formula I or Formula II, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators.
  • PDE4 cyclic nucleotide phosphodiesterase-4
  • the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).
  • cAMP cyclic 3′,5′-adenosine monophosphate
  • Cyclic 3′,5′-adenosine monophosphate (“cAMP”—is a critical intracellular biochemical messenger that is involved in the transduction of the cellular effects of a variety of hormones, neurotransmitters, and other extracellular biological factors in most animal and human cells.
  • the intracellular concentration of cAMP is controlled by the relative balance between its rate of production and degradation.
  • cAMP is generated by biosynthetic enzymes of the adenylyl cyclase superfamily and degraded by members of the cyclic nucleotide phosphodiesterase (PDE) superfamily.
  • PDE cyclic nucleotide phosphodiesterase
  • PDE4 Certain members of the PDE superfamily, such as PDE4, specifically degrade cAMP, while others either specifically degrade cyclic guanosine monophosphate (cGMP) or degrade both cAMP and cGMP. PDE4 enzymes inactivate cAMP, thereby terminating its signalling, by hydrolysing cAMP to 5′-AMP (Lugnier, C. Pharmacol Ther. 109: 366-398, 2006).
  • PDE4A, PDE4B, PDE4C and PDE4D encodes a number of different enzyme isoforms through the use of alternative promoters and mRNA splicing.
  • the catalytically active PDE4 splice variants can be classified as “long”, “short” or “super-short” forms (Houslay, M. D. Prog Nucleic Acid Res Mol Biol. 69: 249-315, 2001).
  • a “dead short” form also exists, which is not catalytically active (Houslay, M. D., Baillie, G. S. and Maurice, D. H. Circ Res. 100: 950-66, 2007).
  • UCR1 and UCR2 upstream conserved regions 1 and 2
  • the UCR1 domain is absent in short forms, whereas the super-short forms not only lack UCR1, but also have a truncated UCR2 domain (Houslay, M. D., Schafer, P. and Zhang, K. Drug Discovery Today 10: 1503-1519, 2005).
  • PDE4 long forms, but not short forms, associate into dimers within cells (Richter, W and Conti, M. J. Biol. Chem. 277: 40212-40221, 2002; Bolger, G. B. et al., Cell. Signal. 27: 756-769, 2015).
  • a proposed negative allosteric modulation of PDE4 long forms by small molecules has been reported (Burgin A. B. et al., Nat. Biotechnol. 28: 63-70, 2010; Gurney M. E. et al., Handb. Exp. Pharmacol. 204: 167-192, 2011).
  • PDE4 long forms may be activated by endogenous cellular mechanisms, such as phosphorylation (MacKenzie, S. J. et al., Br. J. Pharmacol. 136: 421-433, 2002) and phosphatidic acid (Grange et al., J. Biol. Chem. 275: 33379-33387, 2000).
  • Activation of PDE4 long forms by ectopic expression of a 57 amino acid protein (called ‘UCR1C’) whose precise sequence reflects part of that of the upstream conserved region 1 of PDE4D (‘UCR1C’ sequence reflects that of amino acids 80-136 while UCR is amino acids 17-136: numbering based on the PDE4D3 long isoform) has recently been reported (Wang, L. et al., Cell. Signal. 27: 908-922, 2015: “UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy”). The authors hypothesised that PDE4 activation might be used as a potential therapeutic strategy for preventing cardiac hypertrophy.
  • UCR1C 57 amino acid protein
  • Small molecules that act as activators of PDE4 long forms have not previously been disclosed. Small molecule activators would be desirable for a number of reasons, including ease of manufacture and formulation and improved pharmacokinetic properties.
  • the triazole derivative compounds of Formula 1 are shown in the Examples to activate PDE4 long form enzymes, and to provide therapeutically useful effects on cells.
  • the present invention provides a compound of Formula 1 for use in therapy.
  • the therapy is the treatment or prevention of a disease or disorder mediated by excessive intracellular cAMP signalling.
  • a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) should provide a therapeutic benefit.
  • a method of treating or preventing a disease or disorder mediated by excessive intracellular cAMP signalling comprising the step of administering an effective amount of a compound of Formula 1 to a patient in need thereof.
  • the use of a compound of Formula 1 in the manufacture of a medicament for treating or preventing a disease or disorder mediated by excessive intracellular cAMP signalling.
  • the invention also provides a compound of Formula 2, for use in therapy:
  • Compounds of Formula 2 are shown in the Examples to activate a long form cyclic phosphodiesterase-4 (PDE4) enzyme and to provide therapeutically useful effects on cells.
  • PDE4 cyclic phosphodiesterase-4
  • a compound of Formula 1 or Formula 2 can be provided in a pharmaceutical composition comprising a pharmaceutically acceptable excipient.
  • the compounds of the invention are provided for the treatment or prevention of a condition selected from hyperthyroidism, Jansens's metaphyseal chondrodysplasia, hyperparathyroidism, familial male-limited precocious puberty, pituitary adenomas, Cushing's disease, polycystic kidney disease, polycystic liver disease, McCune-Albright syndrome, cholera, whooping cough, anthrax, tuberculosis, HIV, AIDS, Common Variable Immunodeficiency (CVID), melanoma, pancreatic cancer, leukaemia, prostate cancer, adrenocortical tumours, testicular cancer, primary pigmented nodular adrenocortical diseases (PPNAD), Carney Complex, autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), maturity onset diabetes of young type
  • a condition selected from hyperthyroid
  • the invention provides a method of preparing a compound of Formula 1 or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of Formula 1A
  • R1-R15 are defined for Formula 1 above.
  • the invention also provides a method of preparing a compound of Formula 1 or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of Formula 1C
  • R1-R15 are defined for Formula 1 above.
  • the invention provides a method of identifying a compound able to activate a long form PDE4 enzyme, comprising the steps of:
  • the method may be performed according to one of the methods in the Examples.
  • the method further comprises the prior or subsequent step of determining whether the candidate compound activates a short or super-short PDE4 enzyme.
  • a compound that activates a long form PDE4 and does not activate a short or super-short form PDE4 is selective for long form PDE4.
  • One or more of the compounds exemplified herein may be used as the reference or control.
  • FIG. 1 shows activation of PDE4D5, a long form of PDE4, by Examples A, B, D and L;
  • FIG. 2 shows activation of PDE4A4, another long form of PDE4, by Example A;
  • FIG. 3 shows activation of PDE4B1, another long form of PDE4, by Example A;
  • FIG. 4 shows a lack of activation of PDE4B2, a short form of PDE4, by Examples A, B, D and L using the method of Experiment 1, demonstrating selectivity for activation of PDE4 long forms over this PDE4 short form;
  • FIG. 5 shows a reduction in intracellular cAMP levels in HEK293 cells treated with a PDE4 long form activator (10 ⁇ M)—Example A—for 10 min prior to forskolin (F) (10 ⁇ M) for 2 min;
  • FIG. 6 shows a reduction in intracellular cAMP levels in MDCK cells treated with PDE4 long form activators (10 ⁇ M)—Examples A, C and D—for 10 min prior to forskolin (F) (10 ⁇ M) for 2 min;
  • FIG. 7 shows inhibition of in vitro cyst formation in MDCK cells treated with a PDE4 long form activator—Example A—using the method described in Experiment 3, with addition of the specified concentrations of the test compounds every 2 days from day 0 to day 20;
  • FIG. 8 shows a reversal of in vitro cyst formation in MDCK cells treated with a PDE4 long form activator—Example A—using the method described in Experiment 4, with addition of the specified concentrations of the test compounds every 2 days from day 10 to day 20;
  • FIG. 9 shows (normalised cell index at 72 hours) that a PDE4 long form activator—Example A—inhibits the proliferation of androgen-sensitive (AS) LNCaP human prostate cancer cells in a concentration dependent manner, using the method described in Experiment 5;
  • FIG. 10 shows (normalised cell index at 72 hours) that, using the method described in Experiment 5, a PDE4 long form activator—Example A—inhibits the proliferation of androgen-insensitive (AI) LNCaP human prostate cancer cells in a concentration dependent manner;
  • FIG. 11 shows the mouse pharmacokinetic profile of Example A, determined by whole blood analysis at defined time points after i.v. and p.o. administration to male C57 mice;
  • FIG. 12 shows the rat pharmacokinetic profile of Example A, determined by blood plasma analysis at defined time points after i.v. and p.o. administration to male SD rats.
  • FIG. 13 shows (A) concentration dependent inhibition and (B) concentration dependent reversal of in vitro cyst formation in a human patient-derived conditionally immortalised OX161 cell line by Example A.
  • the invention is based on the surprising identification of new compounds that are able to activate long isoforms of PDE4 enzymes.
  • the compounds are small molecules and so are expected to be easier and cheaper to make and formulate into pharmaceuticals than large biological molecules such as polypeptides, proteins or antibodies.
  • the compounds can be chemically synthesized, as demonstrated in the Examples.
  • the Examples demonstrate that a number of compounds of Formula 1 and Formula 2 are able to activate long isoforms of PDE4.
  • the Examples go on to demonstrate that certain tested compounds of the invention: do not activate a short form of PDE4, (thereby demonstrating selectivity for activation of PDE4 long forms over PDE4 short forms); reduce intracellular cAMP levels in human and dog cells; inhibit and even reverse in vitro cyst formation in human and dog cells; inhibit the proliferation of human prostate cancer cells; and have favourable pharmacokinetic properties.
  • the compounds of the invention are therefore surprisingly advantageous.
  • a first aspect provides a compound of Formula 1, as set out above.
  • R 7 and R 11 are H.
  • R 11 , R 12 , R 13 , R 14 and R 15 are H.
  • R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 7 , R 11 , R 12 , R 13 , R 14 and R 15 are H and R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 1 is H, methyl, or methoxy.
  • R 1 is methyl
  • R 2 and R 6 are each independently selected from H and halogen.
  • R 2 and R 6 are each independently selected from H and fluoro.
  • R 2 and R 6 are each H.
  • R 3 , R 4 and R 5 are each independently selected from H, halogen, CN, (C1-4)alkyl and (C1-4)alkyloxy, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 3 and R 5 are each independently selected from H, fluoro, chloro, methoxy, CN, trifluoromethyl, methoxy and trifluoromethoxy.
  • R 4 is selected from H, fluoro and methoxy.
  • R 9 is selected from methyl, chloro and trifluoromethoxy.
  • R 9 is chloro
  • one of R 8 and R 10 is H and the other is fluoro.
  • R 5 and R 15 are both H.
  • R 9 is chloro
  • one of R 8 and R 10 is H and the other of R 8 and R 10 is fluoro.
  • the compound is selected from:
  • a further aspect provides a compound of Formula 2, as set out above.
  • R 7 and R 11 are H.
  • R 11 , R 12 , R 13 , R 14 and R 15 are H.
  • R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 7 , R 11 , R 12 , R 13 , R 14 and R 15 are H and R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 1 is H, methyl, or methoxy.
  • R 1 is methyl
  • R 2 and R 6 are each independently selected from H and halogen.
  • R 2 and R 6 are each independently selected from H and fluoro.
  • R 2 and R 6 are each H.
  • R 3 , R 4 and R 5 are each independently selected from H, halogen, CN, (C1-4)alkyl and (C1-4)alkyloxy, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 3 and R 5 each independently selected from H, fluoro, chloro, methoxy, CN, trifluoromethyl, methoxy and trifluoromethoxy.
  • R 4 is selected from H, fluoro and methoxy.
  • R 9 is selected from methyl, chloro and trifluoromethoxy.
  • one of R 8 and R 10 is H and the other is fluoro.
  • R 8 and R 10 are both H.
  • R 9 is chloro
  • one of R 8 and R 10 is H and the other of R 8 and R 10 is fluoro.
  • R 7 and R 11 are H.
  • R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 7 and R 11 are H and R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 1 is H, methyl, or methoxy.
  • R 1 is methyl
  • R 9 is selected from methyl, chloro and trifluoromethoxy.
  • R 9 is chloro
  • one of R 8 and R 10 is H and the other is fluoro.
  • R 8 and R 10 are both H.
  • R 9 is chloro
  • one of R 8 and R 10 is H and the other of R 8 and R 10 is fluoro.
  • R 7 and R 11 are H.
  • R 11 , R 12 and R 13 are H.
  • R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 7 , R 11 , R 12 and R 13 are H and R 9 is selected from (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros.
  • R 1 is H, methyl, or methoxy.
  • R 1 is methyl
  • R 9 is selected from methyl, chloro and trifluoromethoxy.
  • R 9 is chloro
  • one of R 8 and R 10 is H and the other is fluoro.
  • R 8 and R 10 are both H.
  • R 9 is chloro
  • one of R 8 and R 10 is H and the other of R 8 and R 10 is fluoro.
  • (C1-4)alkyl as used herein means a branched or unbranched alkyl group having 1-4 carbon atoms, optionally containing a ring.
  • Examples of (C1-4)alkyl include butyl, isobutyl, cyclobutyl, tertiary butyl, propyl, isopropyl, cyclopropyl, ethyl and methyl.
  • (C1-4)alkyl may be substituted, for example with 1 to 3 fluoros.
  • a particularly preferred example of a substituted (C1-4)alkyl is trifluoromethyl.
  • (C1-4)alkyl may be unsubstituted.
  • (C1-4)alkyloxy means —O—(C1-4)alkyl wherein (C1-4)alkyl has the meaning as defined above.
  • Examples of (C1-4)alkyloxy include methoxy, ethoxy, propoxy, isopropoxy, butyoxy, isobutoxy and tertiary butoxy.
  • (C1-4)alkyloxy may be substituted, for example with 1 to 3 fluoros.
  • a particularly preferred example of a substituted (C1-4)alkyloxy is trifluoromethoxy.
  • (C1-4)alkyloxy may be unsubstituted.
  • alkyloxy is attached to the rest of the molecule by the “oxy” moiety.
  • halogen means F, Cl, Br or I. F and Cl are particularly preferred.
  • the 1,2,4-triazole derivatives of Formula 1 or 2 may be prepared by methods known in the art of organic chemistry in general. Suitable methods for constructing 1,2,4-triazole rings are, for example, described in the general reference Katritzky, A. R.: Comprehensive heterocyclic chemistry (First Edition, Pergamon Press, 1984, see especially Volume 5, Part 4A, Five-membered rings with two or more nitrogen atoms). Suitable protecting groups for functional groups which are to be temporarily protected during syntheses are known in the art, for example from Wuts, P. G. M. and Greene, T. W.: Protective Groups in Organic Synthesis, Fourth Edition, Wiley, New York, 2006.
  • PDE4 long isoforms have two regulatory regions, upstream conserved region 1 (UCR1) and upstream conserved region 2 (UCR2). These are between the isoform-specific N-terminal portion and the catalytic domain.
  • the UCR1 domain is missing in the short forms, whereas the super-short forms not only lack UCR1, but also have a N-terminal truncated UCR2 domain (Houslay, M. D., Schafer, P. and Zhang, K. Drug Discovery Today 10: 1503-1519, 2005).
  • the present invention concerns compounds that are capable of activating one or more of the long isoforms from one or more of these four families.
  • the long isoform PDE4 may therefore be long isoform PDE4A, long isoform PDE4B, long isoform PDE4C or long isoform PDE4D.
  • a long isoform PDE4 comprises a UCR1 region.
  • the long isoform PDE4 is human.
  • UCR1 is conserved within mammalian species (Houslay, M D, Sullivan, M and Bolger G B Adv Pharmacol. 1998; 44:225-34), so in other embodiments, the long isoform PDE4 can be from a non-human mammal.
  • PDE4 long form activators of Formula I or Formula II of the present invention are small molecules that are believed to bind directly to PDE4 long forms and induce structural changes that increase, stabilise, uncover and/or maintain the catalytic activity of these enzymes.
  • a small molecule is defined as a low molecular weight organic compound that may serve as a regulator of biological processes.
  • a small molecule activator according to the present invention has a molecular weight of less than or equal to 700 Daltons. This allows for the possibility to rapidly diffuse across cell membranes and reach intracellular sites of action (Veber, D. F. et al., J. Med. Chem. 45: 2615-2623, 2002).
  • the preferred molecular weight for a small molecule activator according to the present invention is greater than or equal to 200 Daltons and less than or equal to 600 Daltons.
  • Especially preferred small molecule activators according to the present invention have molecular weights of greater than or equal to 250 Daltons and less than or equal to 500 Daltons (Lipinski, C. A. Drug Discovery Today: Technologies 1: 337-341, 2004).
  • One suitable method of detecting whether or not a compound is capable of serving as an activator of a PDE4 long form is using a two-step radio-assay procedure described in Experiment 1.
  • the method involves incubating a PDE4 long form with a test small molecule activator, together with [ 3 H]-labelled cAMP to assess alterations in the breakdown of cAMP to the 5′-adenosine monophosphate (5′-AMP) product.
  • a sample of the reaction mixture from such an incubation is subsequently treated with snake venom 5′-nucleotidase to allow conversion of the nucleotide [ 3 H]-labelled 5′-AMP to the uncharged nucleoside [ 3 H]-labelled adenosine, which can be separated and quantified to assess PDE4 activity and the effect of the test compound (Thompson, W. J. and Appleman, M. M. Biochemistry 10: 311-316, 1971, with some modifications as described in: Marchmont, R. J. and Houslay, M. D. Biochem J. 187: 381-92, 1980).
  • preferred small molecule activators according to the present invention produce an increase in the background activity of one or more PDE4 long forms of more than 50% at a test compound concentration of 100 micromolar or less.
  • Especially preferred small molecule activators according to the present invention produce an increase in the background activity of one or more PDE4 long forms of more than 50% at a test compound concentration of 10 micromolar, or less, for example 3 micromolar.
  • the compounds of the present invention may be selective for the long form of the PDE4 enzyme and, as such, do not act or act to a lesser extent as activators of the short or super-short isoforms of the PDE4 enzyme.
  • the short or super-short isoform PDE4 may therefore be short or super-short isoform PDE4A, short or super-short isoform PDE4B, short or super-short isoform PDE4C, or short or super-short isoform PDE4D.
  • short and super-short isoforms of PDE4 lack a UCR1 domain.
  • Super-short isoforms comprise a truncated UCR2 domain.
  • the short or super-short isoform PDE4 is human, but may also be from other mammalian species (where UCR2 is conserved, see Houslay, M D, Sullivan, M and Bolger G B Adv Pharmacol. 1998; 44:225-34).
  • the small molecule activators according to the present invention typically produce a less than 50% increase in the background activity of the short or super-short forms of the PDE4A, PDE4B, PDE4C or PDE4D enzymes at a test compound concentration of 100 micromolar, or less.
  • Typical compounds may therefore provide a positive result in an assay for activation of a long form PDE4 and a negative result in an assay for activation of a short form (or super-short form) of PDE4.
  • the compound activates long isoform PDE4A and does not activate either of short and super-short isoform PDE4A.
  • the compound activates long isoform PDE4B and does not activate either of short and super-short isoform PDE4B.
  • the compound activates long isoform PDE4C and does not activate either of short and super-short isoform PDE4C.
  • the compound activates long isoform PDE4D and does not activate either of short and super-short isoform PDE4D.
  • PDE4 long isoforms include those now known as PDE4A4, PDE4A4/5, PDE4A5, PDE4A8, PDE4A10, PDE4A11, PDE4B1, PDE4B3, PDE4B4, PDE4C1, PDE4C2, PDE4C3, PDE4D3, PDE4D4, PDE4D5, PDE4D7, PDE4D8, PDE4D9 and PDE4D11. Further long isoforms may be or have already been identified or called by different nomenclature from any of the four PDE4 sub-families.
  • PDE4 short isoforms include PDE4A1, PDE4B2, PDE4D1 and PDE4D2. Further short isoforms may be or have already been identified or called by different nomenclature from any of the four PDE4 sub-families.
  • PDE4 super-short isoforms include PDE4B5, PDE4D6 and PDE4D10. Further super-short isoforms may be or have already been identified or called by different nomenclature from any of the four PDE4 sub-families.
  • PDE4B Isoform accession SDS-PAGE (kDa) Type B1 L20966 104 L B2 M97515, L20971 68 S B3 U85048 103 L B4 AF202733 84 L B5 EF595686 58
  • the compounds of the present invention may function by reducing cAMP levels in one or more intracellular compartments.
  • the PDE4 long form activators of the present invention may thus provide a means to regulate certain cellular processes that are dependent upon cAMP. Excessive intracellular cAMP signalling mediates a number of diseases and disorders. Therefore, the compounds of the invention are expected to be of utility for the treatment of diseases associated with abnormally elevated cAMP levels, increased cAMP-mediated signalling and/or reduced cAMP elimination, enzymatic or otherwise (e.g. via efflux).
  • the treatment is typically of a human, but may also be of a non-human animal, such as a non-human mammal (e.g. veterinary treatment).
  • the present invention provides a small molecule activator of a PDE4 long form of Formula 1 or Formula 2, for use in a method for the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required.
  • cAMP cyclic 3′,5′-adenosine monophosphate
  • gain-of-function gene mutations in proteins involved in driving cAMP signalling upstream of adenylyl cyclase can lead to abnormal excessive cAMP activity with pathological consequences (Lania A, Mantovani G, Spada A. Ann Endocrinol ( Paris ). 73: 73-75, 2012; Thompson, M. D. et al., Methods Mol. Biol. 448: 109-137, 2008; Weinstein L S, Liu J, Sakamoto A, Xie T, Chen M. Endocrinology. 145: 5459-5464, 2004; Lania A, Mantovani G, Spada A. Eur J Endocrinol.
  • PDE4 long form activators of the present invention possessing the ability to accelerate the termination of cAMP action, would therefore be expected to be effective in the treatment, prevention or partial control of diseases characterised by undesirably high cAMP levels, or activity, as detailed below.
  • TSH thyroid-stimulating hormone
  • TSHR thyroid-stimulating hormone receptor
  • the most common cause of hyperthyroidism is Graves' disease, an autoimmune disorder in which antibodies mimic TSH action at the TSHR, leading to excessive cAMP activity in thyroid follicle cells and consequently a state of hyperthyroidism.
  • PDE4 long form activators of the present invention are therefore expected to be effective in the treatment, prevention or partial control of hyperthyroidism.
  • the hyperthyroidism is associated with Graves' disease.
  • JMC Jansens's Metaphyseal Chondrodysplasia
  • PTH parathyroid hormone receptor 1
  • PTHR1 parathyroid hormone receptor 1
  • the constitutive activation of the PTHR1 which couples to adenylyl cyclase as effector is associated with excessive cAMP signalling primarily in bone and kidney, leading to dysregulation of ion homeostasis characterised by hypercalcemia and hypophosphatemia (Calvi, L. M. and Schipani, E. J. Endocrinol. Invest. 23: 545-554, 2000) and developmental (e.g. short stature) and physical (e.g. protruding eyes) abnormalities.
  • PDE4 long form activators of the present invention are therefore expected to be effective in the treatment, prevention or partial control of JMC and hyperparathyroidism.
  • FMPP Familial male-limited precocious puberty
  • familial sexual precocity or gonadotropin-independent testotoxicosis is a disorder in which boys generally develop signs of precocious puberty in early childhood.
  • FMPP is an autosomal dominant condition with constitutively activating mutations in the luteinizing hormone (LH) receptor, which leads to increased cAMP production, associated with Leydig cell hyperplasia and low sperm cell count (Latronico, A. C. et al., J Clin. Endocrinol. Metab. 80: 2490-2494, 1995; Kosugi, S. et al., Hum. Mol. Genet. 4: 183-188, 1995).
  • LH luteinizing hormone
  • Non-cancerous tumours of the pituitary gland are collectively referred to as pituitary adenomas and can lead to hypersecretion of adenohypophyseal hormones (e.g. growth hormone, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone and adrenocorticotrophic hormone), which exert their action through GPCRs coupled to Gs and cAMP generation.
  • adenohypophyseal hormones e.g. growth hormone, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone and adrenocorticotrophic hormone
  • pituitary adenomas can lead to a state of enhanced cAMP mediated signalling in a variety of endocrine tissues which can precipitate a number of hormonal disorders such as acromegly (mainly due to excess growth hormone secretion), Cushing's disease (due to overproduction of adrenocorticotrophic hormone (ACTH) and the subsequent hypercortisolemia) and/or general hyperpituitarism (associated with excess release of multiple anterior pituitary hormones).
  • Current treatment options for pituitary adenomas include treatment with dopamine receptor agonists, which reduce tumour size and lower pituitary hormonal output through a mechanism involving lowering of intracellular cAMP levels.
  • PDE4 long form activators of the present invention may also be expected to attenuate the pathological effects of pituitary hormones in their target tissues, such as the adrenal glands.
  • PTD Polycystic kidney disease
  • ADPKD autosomal dominant polycystic kidney disease
  • ARPKD autosomal recessive polycystic kidney disease
  • ARPKD affects around 1:20,000 live births and is typically identified in the first few weeks after birth. Pulmonary hypoplasia results in a 30-50% death rate in neonates with ARPKD.
  • ADPKD Alzheimer's disease .
  • PKD1 encoding polycystin-1
  • PC-2 encoding polycystin-2
  • Cyclic AMP has been identified as an important stimulus for proliferation and cyst expansion in polycystic kidney cells but not in normal human kidney cells (Yamaguchi, T. et al., Kidney Int. 57: 1460-1471, 2000).
  • a considerable body of evidence has now developed to implicate cAMP as an important facilitator of renal cystogenesis (Masoumi, A.
  • PDE4 long form activators of the present invention are therefore expected to be effective in the treatment, prevention or partial control of polycystic kidney disease.
  • FIGS. 7 and 8 show the inhibition and reversal of in vitro cyst formation in dog MDCK cells treated with a PDE4 long form activator—Example A—using the methods described in Experiment 3, with addition of the specified concentrations of the test compounds every 2 days from day 0 to day 20, and Experiment 4, with addition of the specified concentrations of the test compounds every 2 days from day 10 to day 20.
  • Example A shows the inhibition and reversal of in vitro cyst formation in human OX161 cells treated with a PDE4 long form activator—Example A—using the methods described in Experiment 9, with addition of the specified concentrations of the test compound every 2 days from day 0 to day 10, and Experiment 10, with addition of the specified concentrations of the test compound every 2 days from day 10 to day 20.
  • PLD Polycystic liver disease
  • Increased cholangiocyte proliferation, neovascularisation and elevated fluid secretion act to drive liver cyst formation through dysregulation of multiple signal transduction pathways, including cAMP-mediated signalling. Elevation of hepatic cAMP levels stimulates cAMP-dependent chloride and fluid secretion in biliary epithelial cells and increases cholangiocyte proliferation (Janssen, M. J. et al., J. Hepatol. 52: 432-440, 2010). Somatostatin, which acts through a Gi-coupled mechanism to lower cAMP levels, reduced cholangiocyte proliferation and fluid secretion (Gong, A. Y. et al., Am. J. Physiol. Cell. Physiol.
  • PDE4 long form activators of the present invention may therefore be effective in the treatment, prevention or partial control of polycystic liver disease due at least in part to cAMP.
  • MODY5 is a form of non-insulin-dependent diabetes mellitus associated with renal cysts. It is an autosomal dominant disorder caused by mutations in the gene encoding hepatocyte nuclear factor-1 ⁇ (HNF-1 ⁇ ).
  • HNF-1 ⁇ hepatocyte nuclear factor-1 ⁇
  • the predominant clinical feature of patients affected by MODY5 is renal dysfunction, frequently diagnosed before the onset of diabetes.
  • HNF-1 ⁇ mutations can result in additional phenotypic features, such as pancreatic atrophy, abnormal liver function and genital tract abnormalities.
  • Studies in mice suggest that the mechanism responsible for renal cyst formation, associated with mutations of HNF-1 ⁇ , involves a severe defect of the transcriptional activation of PKD2, in addition to effects on uromodulin (UMOD) and PKD1 genes.
  • UMOD uromodulin
  • PKD1 and PKD2 Down-regulation of PKD1 and PKD2 is associated with cAMP-driven formation of renal cysts (Mancusi, S. et al., J. Nephrol. 26: 207-12, 2013).
  • HNF-1 ⁇ also binds to the PDE4C promoter and regulates the expression of PDE4C (Ma et al., PNAS 104: 20386, 2007).
  • PDE4 long form activators of the present invention are therefore expected to be effective in the treatment, prevention or partial control of the symptoms of MODY5.
  • Cardiomyocyte hypertrophy is induced via elevated cAMP and activation of its downstream effectors, including PKA and Epac (Wang, L. et al., Cell. Signal. 27: 908-922, 2015 and references therein). Cardiomyocyte hypertrophy increases the risk of heart failure and arrhythmia.
  • PDE4 long form activators of the present invention may therefore be effective in the treatment, prevention or partial control of cardiac hypertrophy, heart failure and/or arrhythmia.
  • GNAS1 Alpha Subunit of the G Protein
  • the G-protein Gs acts as a transducer for GPCRs that stimulate adenylyl cyclase activity and exert their biological effects by increasing intracellular cAMP levels.
  • Gs is a heterotrimeric protein composed of ⁇ , ⁇ and ⁇ subunits. Activating mutations in the gene, GNAS1, for the ⁇ -subunit have been identified which lead to exaggerated abnormal cAMP signalling in a variety of tissues and give rise to a range of disorders.
  • McCune-Albright syndrome is a rare genetic disorder typically characterised by three dominating features of precocious puberty, fibrous dysplasia of bone and café au lait lesions.
  • the underlying molecular pathology for MAS involves an activating mutation of the GNAS1 gene (Diaz, A. Danon, M. and Crawford, J. J. Pediatr. Endocrinol. Metab. 20: 853-880, 2007).
  • PDE4 long form activators of the present invention would therefore be expected to be effective in the treatment, prevention or partial control of disorders associated with activating mutations of GNAS1, including McCune-Albright syndrome.
  • Adenylyl cyclase the enzyme responsible for production of cAMP, is a key biological target thought to be involved in mediating the effects of many bacterial toxins (Ahuja et al., Critical Reviews in Microbiology, 30: 187-196, 2004). These toxins produce their effects by raising cAMP levels through enhancement of host immune cell and/or pathogen related adenylyl cyclase activity. PDE4 long form activators of the present invention, by reducing cAMP levels, would therefore be expected to be of utility in the treatment or partial control of symptoms of infectious diseases that are associated with elevated cAMP activity. The following are some examples of such infectious diseases:
  • Vibrio cholerae produces cholera toxin, which through adenosine disphosphate ribosylation of the ⁇ subunit of Gs leads to host cell adenylyl cyclase activation and cAMP production. Diarrhoea caused by cholera toxin is believed to be a result of excessive cAMP accumulation in the cells of the gastrointestinal tract.
  • Bordetella pertussis is the pathogen responsible for the childhood disease whooping cough. Bordetella pertussis toxin stimulates adenosine disphosphate ribosylation of the ⁇ subunit of Gi and indirectly augments cAMP levels in target cells. The bacterium also secretes an invasive adenylyl cyclase, which produces toxic cAMP levels and impairs host immune defence.
  • Anthrax is caused by Bacillus anthracis and whilst it is primarily an animal disease it can be transmitted to humans through contact.
  • Anthrax infections are associated with widespread oedema, the development of which is thought to be driven by oedema toxin.
  • the latter is an adenylyl cyclase and is activated by host calmodulin to produce abnormally high levels of cAMP that have a toxic effect on host immune cells.
  • Mycobactrium tuberculosis expresses a large and diverse range of adenylyl cyclases, which may play a role in virulence and generation of disease pathology.
  • adenylyl cyclase subtype RV0386
  • RV0386 adenylyl cyclase subtype
  • PDE4 long form activators of the present invention may therefore be effective in the treatment, prevention or partial control of infectious diseases such as cholera, whooping cough, anthrax and tuberculosis.
  • cAMP activates protein kinase A (PKA), which is also known as cAMP-dependent protein kinase.
  • PKA protein kinase A
  • PKA is normally inactive as a tetrameric holoenzyme, consisting of two catalytic and two regulatory units, with the regulatory units blocking the catalytic centres of the catalytic units.
  • cAMP binds to specific locations on the regulatory units of PKA and causes dissociation between the regulatory and catalytic units, thus activating the catalytic units.
  • the active catalytic units catalyse the transfer of phosphate from ATP to specific residues of protein substrates, which may modulate the function of those protein substrates.
  • PDE4 long form activation reduces cAMP levels and cAMP mediated activation of PKA.
  • PDE4 long form activators of the present invention would therefore be expected to be of utility in the treatment or partial control of disorders where inhibitors of PKA show evidence of therapeutic effects.
  • Rp-8-Br-cAMPS is an analogue of cAMP that occupies the cAMP binding sites of PKA, preventing its dissociation and activation.
  • T cells from HIV-infected patients have increased levels of cAMP and are more sensitive to inhibition by Rp-8-Br-cAMPS than are normal T cells.
  • Excessive activation of PKA by cAMP has been associated with the progressive T cell dysfunction in HIV infection (Aandahl, E. M. et al., FASEB J. 12: 855-862, 1998).
  • Rp-8-Br-cAMPS has been shown to restore T cell responses in retrovirus-infected mice (Nayjib, B. et al., The Open Immunology Journal, 1: 20-24, 2008).
  • PDE4 long form activators of the present invention are therefore expected to be of utility in the treatment, prevention or partial control of HIV infection and AIDS.
  • CVID Common Variable Immunodeficiency
  • Epac exchange protein directly activated by cAMP
  • Epac1 and Epac2 are two isoforms of Epac, both consisting of a regulatory region that binds cAMP and a catalytic region that promotes the exchange of GDP for GTP on the small G proteins, Rap1 and Rap2 of the Ras family.
  • Epac proteins exert their functions through interactions with a number of other cellular partners at specific cellular loci. Pathophysiological changes in Epac signalling have been associated with a wide range of diseases (Breckler, M. et al., Cell. Signal. 23: 1257-1266, 2011).
  • Epac inhibitors such as ESI-09, a novel non-cyclic nucleotide Epac1 and Epac2 antagonist that is capable of specifically blocking intracellular Epac-mediated Rapt activation and Akt phosphorylation, as well as Epac-mediated insulin secretion in pancreatic beta cells (Almahariq, M. et al., Mol. Pharmacol. 83: 122-128, 2013).
  • Epac1 has been implicated in promoting migration and metastasis in melanoma (Baljinnyam, E. et al., Pigment Cell Melanoma Res. 24: 680-687, 2011 and references cited therein).
  • PDE4 long form activators of the present invention are therefore expected to be of utility in the treatment, prevention or partial control of melanoma.
  • Epac1 is markedly elevated in human pancreatic cancer cells as compared with normal pancreas or surrounding tissue (Lorenz, R. et al., Pancreas 37: 102-103, 2008).
  • Pancreatic cancer is often resistant to treatments that are usually effective for other types of cancer.
  • Epac inhibitor ESI-09 a functional role of Epac1 overexpression in pancreatic cancer cell migration and invasion was demonstrated (Almahariq, M. et al., Mol. Pharmacol. 83: 122-128, 2013).
  • PDE4 long form activators of the present invention would therefore be expected to be of utility in the treatment, prevention or partial control of pancreatic cancer.
  • PDE4 long form activators of the present invention would therefore be expected to be of utility in the treatment of disorders where inhibitors of cAMP-gated ion channels show evidence of therapeutic effects.
  • cAMP response element binding protein is an important transcription factor involved in the regulation of a variety of cellular functions such as cell proliferation, differentiation, survival, and apoptosis (Cho et al., Crit Rev Oncog, 16: 37-46, 2011).
  • CREB activity is regulated by kinase dependant phosphorylation through a range of extracellular signals, such as stress, growth factors and neurotransmitters. Phosphorylation leads to dimerisation of CREB, and together with other co-activator partner proteins, enables it to bind to promoter regions of target genes containing the cAMP response element (CRE sites) and initiate transcriptional activity.
  • the cAMP pathway e.g.
  • PDE4 long form activators of the present invention are therefore expected to be of utility in the treatment, prevention or partial control of disorders associated with elevated CREB activity.
  • Bone marrow cells from acute lymphoid and myeloid leukaemia patients have been reported to overexpress CREB protein and mRNA (Crans-Vargas et al., Blood, 99: 2617-9, 2002; Cho et al., Crit Rev Oncog, 16: 37-46, 2011). Furthermore, the increased CREB level correlates with poor clinical response in subjects with acute myeloid leukaemia (Grans-Vargas et al., Blood, 99: 2617-9, 2002; Shankar et al., Cancer Cell, 7:351-62, 2005). Upregulation of CREB is associated with stimulation of human leukaemia cell growth whilst downregulation inhibits myeloid cell proliferation and survival.
  • PDE4 long form activators of the present invention would be expected to reduce CREB activity and function through attenuation of cAMP mediated stimulation of CREB and therefore expected to have utility in the treatment, prevention or partial control of acute lymphoid and myeloid leukaemia.
  • Abnormal excessive androgen activity is an important driver in the development of prostate cancer as it stimulates the development of intraepithelial neoplasias (Merkle et al., Cellular Signalling, 23: 507-515, 2011). This is strongly supported by the use of androgen ablation approaches, involving chemical or surgical castration, in the treatment of prostate cancer.
  • Cyclic AMP elevating agents such as forskolin can enhance androgen receptor activity through multiple intracellular mechanisms including androgen receptor activation through phosphorylation and/or interaction with CREB.
  • Epac1 activation has also been implicated in promoting cellular proliferation in prostate cancer (Misra, U. K. and Pizzo, S. V. J. Cell. Biochem.
  • PDE4 long form activators of the present invention are therefore expected to have utility in the treatment, prevention or partial control of prostate cancer.
  • Adrenocortical tumours associated with an inactivating point mutation in the gene encoding PDE11A4 have decreased expression of PDE11A4 and increased cAMP levels (Horvath, A. et al., Nat Genet. 38: 794-800, 2006; Horvath, A. et al., Cancer Res. 66: 11571-11575, 2006; Libe, R., et al., Clin. Cancer Res. 14: 4016-4024, 2008).
  • PNAD Primary Pigmented Nodular Adrenocortical Diseases
  • Mutations in the PDE8B gene have also been identified as a predisposing factor for PPNAD and the mutant protein shows reduced ability to degrade cAMP (Horvath, A., Mericq, V. and Stratakis, C. A. N. Engl. J. Med. 358: 750-752, 2008; Horvath, A. et al., Eur. J. Hum. Genet. 16: 1245-1253, 2008).
  • CNC Carney Complex
  • treatment herein is meant the treatment by therapy, whether of a human or a non-human animal (e.g., in veterinary applications) typically a non-human mammal, in which some desired therapeutic effect on the condition is achieved; for example, the inhibition of the progress of the disorder, including a reduction in the rate of progress, a halt in the rate of progress, amelioration of the disorder or cure of the condition.
  • Treatment as a prophylactic measure is also included.
  • References herein to prevention or prophylaxis herein do not indicate or require complete prevention of a condition; its manifestation may instead be reduced or delayed via prophylaxis or prevention according to the present invention.
  • a “therapeutically effective amount” herein is meant an amount of the one or more compounds of the invention or a pharmaceutical formulation comprising such one or more compounds, which is effective for producing such a therapeutic effect, commensurate with a reasonable benefit/risk ratio.
  • appropriate dosages of the compounds of the invention may vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention.
  • the selected dosage level will depend on a variety of factors including the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination and the age, sex, weight, condition, general health and prior medical history of the patient.
  • the amount of compound(s) and route of administration will ultimately be at the discretion of the physician, although generally the dosage will be to achieve local concentrations at the site of action so as to achieve the desired effect.
  • Administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to a person skilled in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
  • a suitable dose of the one or more compounds of the invention may be in the range of about 0.001 to 50 mg/kg body weight of the subject per day, preferably in a dosage of 0.01-25 mg per kg body weight per day, e.g., 0.01, 0.05, 0.10, 0.25, 0.50, 1.0, 2.5, 10 or 25 mg/kg per day.
  • the compound(s) is a salt, solvate, prodrug or the like
  • the amount administered may be calculated on the basis of the parent compound and so the actual weight to be used may be increased proportionately.
  • the compounds of the invention may also find application in mimicking or enhancing the effects of drugs known to produce their therapeutic effect through lowering of intracellular cAMP levels.
  • a number of therapeutically beneficial drugs have a primary mode of action involving lowering intracellular cAMP levels and/or cAMP-mediated activity, as summarised below. Since PDE4 long form activators of the present invention will also act to lower cAMP levels it is expected that these agents will mimic and/or augment the pharmacological properties and therapeutic utility of drugs operating through a down-regulation of cAMP-mediated signalling.
  • a compound of the invention is therefore provided as part of a combination therapy with another agent that lowers intracellular cAMP levels and/or cAMP-mediated activity.
  • the combination therapy may be administered simultaneously, contemporaneously, sequentially or separately.
  • the compound of the invention and the separate cAMP lowering agent are provided in a single composition, as described in more detail below.
  • the combination therapy may comprise a compound of the invention and one or more of:
  • ⁇ -2 Adrenergic receptor stimulation is known to reduce cAMP levels through a G i protein-mediated inhibition of adenylyl cyclase activity in a broad range of tissues.
  • presynaptic ⁇ -2 adrenergic receptor activation inhibits noradrenaline release and noradrenergic activity.
  • Drugs e.g. clonidine, dexmedetomidine, guanfacine
  • clonidine, dexmedetomidine, guanfacine that act as agonists at these receptors are effective in the treatment of a variety of clinical conditions.
  • Clonidine the prototypic agent, has shown therapeutic utility in the treatment of hypertension, neuropathic pain, opioid detoxification, insomnia, ADHD, Tourette syndrome, sleep hyperhidrosis, addiction (narcotic, alcohol and nicotine withdrawal symptoms), migraine, hyperarousal, anxiety and also as a veterinary anaesthetic.
  • Lowering of cAMP levels by PDE4 long form activation may be expected to yield similar effects to drugs acting through ⁇ -2 adrenergic receptor stimulation.
  • PDE4 long form activators of the present invention may be expected to potentiate the pharmacodynamic effects of ⁇ -2 adrenergic receptor agonists when used in combination.
  • ⁇ -1 Adrenergic receptor antagonists are used in the treatment a range of cardiovascular indications including hypertension, cardiac arrhythmias and cardioprotection following myocardial infarction. Their primary mechanism of action involves reducing the effects of excessive circulating adrenaline and sympathetic activity, mediated by noradrenaline, particularly at cardiac ⁇ -1 adrenergic receptors. Endogenous and synthetic ⁇ -1 adrenergic receptor agonists stimulate adenylyl cyclase activity through G s activation and raise intracellular cAMP levels in a variety of tissues such as heart and kidney. Consequently, drugs that block ⁇ -1 adrenergic receptor mediated activity exert their pharmacological effects by attenuating the increase in cAMP mediated signalling.
  • PDE4 long form activators of the present invention may be expected to find utility in the treatment or partial control of hypertension, cardiac arrhythmias, congestive heart failure and cardioprotection. Additional non-cardiovascular therapeutic utility may be expected in disorders such as post-traumatic stress related disorder, anxiety, essential tremor and glaucoma, which also respond to ⁇ -1 adrenergic antagonist treatment. Furthermore, PDE4 long form activators of the present invention may be expected to potentiate the pharmacodynamic effects of ⁇ -1 adrenergic receptor antagonists when used in combination.
  • the present invention provides a small molecule activator of a PDE4 long form of Formula 1 or Formula 2 for use in a method for the treatment or prevention of a disease or disorder in a patient in need of such therapy.
  • the disease or disorder may be any disease of disorder described herein, including: a disease associated with increased cAMP production and signalling (such as hyperthyroidism, Jansens's metaphyseal chondrodysplasia, hyperparathyroidism, familial male-limited precocious puberty, pituitary adenomas, Cushing's disease, polycystic kidney disease, polycystic liver disease, MODY5 and cardiac hypertrophy); diseases known to be associated with increased cAMP-mediated signalling, including disorders associated with activating mutations of the alpha subunit of the G protein (GNAS1) (such as McCune-Albright syndrome); amelioration of toxin-induced increases in adenylyl cyclase activity in infectious diseases (such as chol
  • the terms “compound of the invention”, “compound of Formula 1”, “compound of Formula 2” etc. include pharmaceutically acceptable derivatives thereof and polymorphs, isomers and isotopically labelled variants thereof. Furthermore, these terms include all the sub-embodiments of those compounds disclosed herein.
  • compositions comprising a compound of the invention, including a pharmaceutically acceptable salt, solvate, ester, hydrate or amide thereof, in admixture with a pharmaceutically acceptable excipient(s), and optionally other therapeutic agents.
  • accepted means being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
  • Compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, epidural, intrathecal, intramuscular, transdermal, intranasal, pulmonary, topical, local, or rectal administration, and the like, typically in unit dosage forms for administration.
  • pharmaceutically acceptable salt includes a salt prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic or organic acids and bases.
  • Compounds of the invention which contain basic, e.g. amino, groups are capable of forming pharmaceutically acceptable salts with acids.
  • Examples of pharmaceutically acceptable acid addition salts of the compounds according to the invention include acid addition salts formed with organic carboxylic acids such as acetic, lactic, tartaric, maleic, citric, pyruvic, oxalic, fumaric, oxaloacetic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.
  • organic carboxylic acids such as acetic, lactic, tartaric, maleic, citric, pyruvic, oxalic, fumaric, oxaloacetic, isethionic, lactobionic and succinic acids
  • organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzen
  • Pharmaceutically acceptable basic salts of the compounds of the invention include, but are not limited to, metal salts such as alkali metal or alkaline earth metal salts (e.g. sodium, potassium, magnesium or calcium salts) and zinc or aluminium salts and salts formed with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines (e.g. diethanolamine), benzylamines, N-methyl-glucamine, amino acids (e.g. lysine) or pyridine.
  • metal salts such as alkali metal or alkaline earth metal salts (e.g. sodium, potassium, magnesium or calcium salts) and zinc or aluminium salts and salts formed with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines (e.g. diethanolamine), benzylamines, N-methyl-glucamine, amino acids (e.g. lysine) or pyridine.
  • Hemisalts of acids and bases may also be formed, e.g. hemisulphate salts.
  • compositions of the compounds of the invention may be prepared by methods well-known in the art.
  • pharmaceutically acceptable salts see Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection and Use (Wiley-VCH, Weinheim, Germany, 2002).
  • the invention includes prodrugs of the compounds of Formulae 1 and 2.
  • Prodrugs are derivatives of compounds of Formula 1 or 2 (which may have little or no pharmacological activity themselves), which can, when administered in vivo, be converted into compounds of Formula 1 or 2.
  • Prodrugs can, for example, be produced by replacing functionalities present in the compounds of Formula 1 or 2 with appropriate moieties which are metabolized in vivo to form a compound of Formula 1 or 2.
  • the design of prodrugs is well-known in the art, as discussed in Bundgaard, Design of Prodrugs 1985 (Elsevier), The Practice of Medicinal Chemistry 2003, 2 nd Ed, 561-585 and Leinweber, Drug Metab. Res. 1987, 18: 379.
  • prodrugs of compounds of Formula 1 or 2 are amides and esters of those compounds.
  • the compound of Formula 1 or 2 contains a carboxylic acid group (—COOH)
  • the hydrogen atom of the carboxylic acid group may be replaced in order to form an ester (e.g. the hydrogen atom may be replaced by C 1-6 alkyl).
  • the hydrogen atom of the alcohol group may be replaced in order to form an ester (e.g. the hydrogen atom may be replaced by —C(O)C 1-6 alkyl.
  • solvate is used herein to refer to a complex of solute, such as a compound or salt of the compound, and a solvent. If the solvent is water, the solvate may be termed a hydrate, for example a mono-hydrate, di-hydrate, tri-hydrate etc, depending on the number of water molecules present per molecule of substrate.
  • the compounds of the present invention may exist in various stereoisomeric forms and the compounds of the present invention as hereinbefore defined include all stereoisomeric forms and mixtures thereof, including enantiomers and racemic mixtures.
  • the present invention includes within its scope the use of any such stereoisomeric form or mixture of stereoisomers, including the individual enantiomers of the compounds of Formula 1 or 2 as well as wholly or partially racemic mixtures of such enantiomers.
  • isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques).
  • isomers can be prepared by the application or adaptation of known methods (e.g. asymmetric synthesis).
  • the invention includes pharmaceutically acceptable isotopically-labelled compounds of Formula 1 or 2 wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 38 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, and sulphur, such as 35 S.
  • isotopically-labelled compounds of Formula 1 or 2 for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes 3 H and 14 C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • Isotopically-labelled compounds of Formula 1 or 2 can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.
  • the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
  • Formulations suitable for oral administration may also be designed to deliver the compounds of the invention in an immediate release manner or in a rate-sustaining manner, wherein the release profile can be delayed, pulsed, controlled, sustained, or delayed and sustained or modified in such a manner which optimises the therapeutic efficacy of the said compounds.
  • Means to deliver compounds in a rate-sustaining manner are known in the art and include slow release polymers that can be formulated with the said compounds to control their release.
  • rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the said compounds by diffusion or a combination of diffusion and polymer erosion.
  • rate-sustaining polymers include hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide and polyethylene glycol.
  • Liquid (including multiple phases and dispersed systems) formulations include emulsions, suspensions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents 2001, 11(6): 981-986.
  • the active ingredient may be presented in the form of a dry powder from a dry powder inhaler or in the form of an aerosol spray of a solution or suspension from a pressurised container, pump, spray, atomiser or nebuliser.
  • the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
  • sterile liquid carrier e.g. water
  • the compounds of the invention may be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ.
  • Suitable means for administration include intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous.
  • Suitable devices for administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water (WFI).
  • excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water (WFI).
  • WFI sterile, pyrogen
  • Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
  • degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides.
  • parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
  • the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules, suppositories or patches.
  • the active agent can be applied as a fluid composition, e.g. as an injection preparation or as an aerosol spray, in the form of a solution, suspension, or emulsion.
  • solid dosage units For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive that does not interfere with the function of the active compounds can be used. Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotonic saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
  • the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
  • the one or more compounds of the present invention may be used in combination therapies for the treatment of the described conditions i.e., in conjunction with other therapeutic agents.
  • the two or more treatments may be given in individually varying dose schedules and via different routes.
  • a compound of the invention is administered in combination therapy with one, two, three, four or more, preferably one or two, preferably one other therapeutic agents
  • the compounds can be administered simultaneously or sequentially.
  • they can be administered at closely spaced intervals (for example over a period of 5-10 minutes) or at longer intervals (for example 1, 2, 3, 4 or more hours apart, or even longer period apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).
  • the invention provides a product comprising a compound of the invention and another therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required.
  • Products provided as a combined preparation include a composition comprising a compound of the invention and the other therapeutic agent together in the same pharmaceutical composition, or the compound of the invention and the other therapeutic agent in separate form, e.g. in the form of a kit.
  • the invention provides a pharmaceutical composition comprising a compound of the invention and another therapeutic agent.
  • the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.
  • the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention.
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for administration.
  • the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
  • the invention also provides the use of a compound of the invention in the manufacture of a medicament for the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the medicament is prepared for administration with another therapeutic agent.
  • the invention also provides the use of another therapeutic agent in the manufacture of medicament for treating a disease or condition mediated by cAMP for the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the medicament is prepared for administration with a compound of the invention.
  • the invention also provides a compound of the invention for use in the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the compound of the invention is prepared for administration with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the other therapeutic agent is prepared for administration with a compound of the invention.
  • the invention also provides a compound of the invention for use in for the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the compound of the invention is administered with another therapeutic agent.
  • cAMP cyclic 3′,5′-adenosine monophosphate
  • the invention also provides another therapeutic agent for use in the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the other therapeutic agent is administered with a compound of the invention.
  • the invention also provides the use of a compound of the invention in the manufacture of a medicament for the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent.
  • the invention also provides the use of another therapeutic agent in the manufacture of a medicament for the treatment or prevention of disorders where a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) is required, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of the invention.
  • the other therapeutic agent is:
  • Table 1 shows examples of novel small molecule PDE4 long form activators of Formula 1 and Formula 2 (Examples A to L), according to the present invention
  • Table 2 shows activation of PDE4D5, a long form of PDE4, by Examples A to L.
  • Table 3 shows activation of PDE4A4, another long form of PDE4, by Example A.
  • Table 4 shows activation of PDE4B1, another long form of PDE4, by Example A.
  • FIG. 1 shows activation of PDE4D5, a long form of PDE4, by Examples A, B, D and L.
  • FIG. 2 shows activation of PDE4A4, another long form of PDE4, by Example A.
  • FIG. 3 shows activation of PDE4B1, another long form of PDE4, by Example A.
  • FIG. 4 shows a lack of effect on PDE4B2, a short form of PDE4, Examples A, B, D and L.
  • FIG. 5 shows a reduction in intracellular cAMP levels in HEK 293 cells treated with a PDE4 long form activator of the present invention (10 ⁇ M) for 10 min prior to forskolin (F) (10 ⁇ M) for 2 min.
  • FIG. 6 shows a reduction in intracellular cAMP levels in Madin-Darby canine kidney (MDCK) cells treated with PDE4 long form activators of the present invention (10 ⁇ M) for 10 min prior to forskolin (F) (10 ⁇ M) for 2 min.
  • FIG. 7 shows inhibition of in vitro cyst formation in MDCK cells treated with a PDE4 long form activator of the present invention.
  • FIG. 8 shows reversal of in vitro cyst formation in MDCK cells treated with a PDE4 long form activator of the present invention.
  • FIG. 9 shows inhibition of proliferation of androgen-sensitive (AS) LNCaP human prostate cancer cells treated with a PDE4 long form activator of the present invention.
  • FIG. 10 shows inhibition of proliferation of androgen-insensitive (AI) LNCaP human prostate cancer cells treated with a PDE4 long form activator of the present invention.
  • FIG. 11 shows the in vivo mouse pharmacokinetic profile of Example A, determined by whole blood analysis at defined time points after i.v. and p.o. administration to male C57 mice.
  • FIG. 12 shows the in vivo rat pharmacokinetic profile of Example A, determined by blood plasma analysis at defined time points after i.v. and p.o. administration to male SD rats.
  • FIG. 13 shows (A) inhibition and (B) reversal of in vitro cyst formation in OX161 cells treated with Example A, a PDE4 long form activator of the present invention.
  • NMR spectra were recorded using a Bruker AV300 spectrometer at 25° C. The following abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet), dd (doublet of doublet), dt (doublet of triplet).
  • Step 3 4-Chloro-3-fluorobenzene carboximidic acid methyl ester, hydrochloride salt
  • Step 4 3-(4-Chloro-3-fluorophenyl)-5-ethyl-1H-1,2,4-triazole
  • Step 5 N-(3-Fluorobenzyl)-2-[3-(4-chloro-3-fluorophenyl)-5-ethyl-1H-1,2,4-triazol-1-yl]acetamide
  • N-benzyl-2-iodoacetamide Trituration with an ethyl acetate/dichloromethane mixture followed by filtration afforded N-benzyl-2-iodoacetamide (3.91 g). The filtrate was concentrated under reduced pressure and purified by flash column chromatography eluting with 50% chloroform/ethyl acetate to afford further product (2.35 g). The pad of Celite® was further washed with dichloromethane and then chloroform to afford further product (7.10 g). The product samples were combined and dried in air to afford a single batch of N-benzyl-2-iodoacetamide as a white powder (13.14 g, 47.76 mmol).
  • the title compound was prepared according to the method of Example B, using acethydrazide instead of methoxyacetic acid hydrazide.
  • the title compound was prepared according to the method of Example B, steps 3 and 4, using 4-(trifluoromethoxy)benzonitrile instead of 4-chlorobenzonitrile and N-(3-fluorobenzyl)-2-iodoacetamide (as prepared in Example A) instead of N-benzyl-2-iodoacetamide.
  • Step 1 3-(4-Chloro-3-fluorophenyl)-5-ethyl-1H-1,2,4-triazole
  • the triazole was prepared according to the method of Example B, step 3, using 4-chloro-3-fluorobenzonitrile instead of 4-chlorobenzonitrile and propionic acid hydrazide instead of methoxyacetic acid hydrazide.
  • Step 2 O-tert-butyl-2[3-(4-chloro-3-fluorophenyl)-5-ethyl-1H-1,2,4-triazol-1-yl]acetate
  • Step 3 2-[3-(4-Chloro-3-fluorophenyl)-5-ethyl-1H-1,2,4-triazol-1-yl]acetic acid
  • Step 4 2-[3-(4-Chloro-3-fluorophenyl)-5-ethyl-1H-1,2,4-triazol-1-yl]acetyl chloride
  • Step 5 N-(3-Chlorobenzyl)-2-[3-(4-chloro-3-fluorophenyl)-5-ethyl-1H-1,2,4-triazol-1-yl]acetamide
  • HEK 293 and MDCK cells Public Health England, Cell Culture Collections
  • DMEM fetal bovine serum
  • 2 mM L-glutamine 1,000 U penicillin and 1,000 ⁇ g streptomycin (Life Technologies); termed complete media.
  • Clonal HEK 293 cell lines were maintained in complete media supplemented with 0.6 mg/mL G418 (Enzo Life Sciences).
  • HEK 293 cells were transfected with pDESTTM PDE4 expression vectors using Lipofectamine LTX/Plus reagent (Invitrogen) as outlined by the manufacturer and clonal isolates expanded to obtain cell lines that stably expressed the full-length human PDE4D5, PDE4A4 and PDE4B1 long isoforms and the full length human PDE4B2 short isoform. These were called the HEK-PDE4D5, HEK-PDE4A4, HEK-PDE4B1 and HEK-PDE4B2 cell lines, respectively.
  • HEK-PDE4D5 cells were seeded out in 100 mm plates and incubated at 37° C. in an atmosphere of 5% CO 2 , 95% air.
  • Cell lysates were prepared using KHEM buffer [50 mM KCl, 10 mM EGTA, 50 mM HEPES (pH 7.2), 1.92 mM MgCl 2 ].
  • the 100 mm plates containing the cells were placed on ice and washed with ice-cold PBS (phosphate buffered saline, pH 7.4). KHEM buffer (500 ⁇ l) was added to the cells. Cells were then scraped off the plate and triturated using a needle (BD MicrolanceTM 0.8, 40 mm). The lysed cells were then centrifuged at 2000 rpm for 10 minutes to remove cell debris and the supernatant (cell lysate containing recombinant PDE4D5) was transferred to a fresh tube and kept on ice.
  • PBS phosphate buffered saline, pH 7.4
  • KHEM buffer 500 ⁇ l
  • Cells were then scraped off the plate and triturated using a needle (BD MicrolanceTM 0.8, 40 mm).
  • the lysed cells were then centrifuged at 2000 rpm for 10 minutes to remove cell debris and the supernatant (cell lysate containing recombinant P
  • the cell lysate containing recombinant PDE4D5 was transferred into a centrifuge tube and placed into an ultracentrifuge (BECKMAN COULTER) and spun at high speed (100,000 g) for 30 minutes at 4° C. The cytosol fraction was then collected and its protein amount determined using a BCA protein assay.
  • PDE assays were performed using a final concentration of 10 mM Tris/5 mM MgCl 2 and 1 ⁇ M [3H]-cAMP (Perkin Elmer) plus PDE4D5 cell lysate cytosol fraction, containing over-expressed PDE4D5, with and without test compound. Incubations were performed at 30° C. for 5 minutes. The samples were then placed in a boiling water bath for 2 minutes to denature the PDE enzyme, and returned to ice. Samples were allowed to cool for 10 min after which snake venom 5′-nucleotidase (25 ⁇ l, 1 mg/ml; Sigma) was added. The tubes were vortexed and incubated in a water bath at 30° C.
  • FIGS. 1 to 4 Data are shown in graphical form in FIGS. 1 to 4 .
  • HEK 293 or MDCK cells were seeded at 100,000 cells per well, and left to adhere overnight. The cells were then treated with the compound indicated (10 ⁇ M) for 10 minutes, prior to stimulation with forskolin (10 ⁇ M, Sigma) for 2 minutes. Media was aspirated, and hydrochloric acid (0.1M) was added to lyse the cells. The cAMP assay (Enzo Life Sciences) was performed according to the manufacturer's instructions.
  • Compounds of the present invention reduced intracellular cAMP levels in forskolin stimulated HEK 293 or MDCK cells.
  • FIGS. 5 and 6 Data are shown in graphical form in FIGS. 5 and 6 .
  • 3D cysts were generated based on the method of Mao et al. (Mao, Z., Streets, A. J., Ong, A. C. M. Am. J. Physiol. Renal Physiol. 300(6): F1375-F1384, 2011), with some modifications.
  • MDCK cells (50,000 cells/well) were seeded into collagen (Life Technologies; final concentration 1 mg/mL), containing 17 mM NaOH in DMEM, supplemented with 2% (v/v) FBS, 2 mM L-glutamine and 2 mM L-glutamine, 1,000 U penicillin and 1,000 ⁇ g streptomycin (DMEM-2% FBS), on ice.
  • DMEM-2% FBS a DMEM-2% FBS
  • 1 mL of DMEM-2% FBS was added along with the test compound indicated in the presence of 10 ⁇ M forskolin (Sigma) and 1 ⁇ g/mL [Arg 8 ]-vasopressin acetate salt (Sigma).
  • Media was replenished every 2 days for 20 days; at every feed, test compound, forskolin and vasopressin were added.
  • Phase-contrast images were obtained on the Motic microscope ( ⁇ 200 magnification) every 2 days for 20 days. Per condition, 10 images were taken (in duplicate) and the average cyst radius measured.
  • Example A The day 20 phase-contrast images and cyst radius graphs for Example A are shown in FIG. 7 .
  • Phase-contrast images were obtained on the Motic microscope ( ⁇ 200 magnification) every 2 days for 20 days. Per condition, 10 images were taken (in duplicate) and the average cyst radius measured.
  • Example A The day 20 phase-contrast images and cyst radius graphs for Example A are shown in FIG. 8 .
  • Androgen-sensitive (AS) LNCaP cells were maintained in RPM11640 supplemented with 10% FBS (Seralabs), 2 mM L-glutamine and 1,000 U penicillin-streptomycin.
  • LNCaP androgen-insensitive (AI) cells were generated in-house by culturing the LNCaP-AS cells in RPM11640 supplemented with 10% charcoal stripped FBS, 2 mM L-glutamine and 1,000 U penicillin-streptomycin for a minimum of four weeks. All tissue culture reagents were from Life Technologies.
  • Cell proliferation is measured as a function of changing electrical impedance. Values are represented by cell index number, a dimensionless unit of measurement representing the cell status, which increases as cells adhere to 96-well electrode plates and divide.
  • LNCaP AI/AS cells were plated at a density of 25,000 cells per well in a 96-well electrode plate (in triplicate), in the presence/absence of various concentrations of test compound.
  • Example A The effects of Example A on proliferation of androgen-sensitive (AS) LNCaP human prostate cancer cells are shown in FIG. 9 .
  • Example A The effects of Example A on proliferation of androgen-insensitive (AI) LNCaP human prostate cancer cells are shown in FIG. 10 .
  • Human hepatocyte stability is considered the gold standard method for evaluating the hepatic metabolism of drugs in vitro.
  • the in vitro clearance of Example A was evaluated using cryopreserved human hepatocytes according to the method of Lau et al. (Lau, Y. Y. et al. Drug Metab. Dispos. 30: 1446-1454, 2002) with minor modifications.
  • Cryopreserved hepatocytes were thawed in a water bath at 37° C. and transferred to a tube containing 50 ml of hepatocyte thaw medium.
  • the hepatocytes were centrifuged at 500 rpm for 3 min.
  • the supernatant was removed and the hepatocytes were resuspended in medium, mixed gently and centrifuged again at 500 rpm for 3 min.
  • the supernatant was discarded and the hepatocyte pellet was gently resuspended in medium to a final density of 2 million cells/ml.
  • Incubations were carried out at a final test compound concentration of 1 ⁇ M. Stock solutions of the compounds were prepared in DMSO and diluted to the desired concentrations before adding to the hepatocytes. Incubations were carried out with a hepatocyte concentration of 1 million cells/ml. Samples (100 ⁇ L) were incubated at 37° C. for 0, 15, 30, 60 and 120 min in duplicate. At the end of the incubation time, 200 ⁇ l of acetonitrile with internal standard was added and the wells were sealed.
  • the samples were sonicated for 2 min and centrifuged at 6000 rpm for 10 min, and 50 ⁇ L of the supernatant was transferred into a 96-well plate containing 50 ⁇ L of ultrapure water for LC-MS/MS analysis.
  • Example A was moderately stable in human hepatocytes.
  • Example A was dissolved in 5% DMA+10% Solutol+85%(10% HPBCD in water) to afford a clear dosing solution of 1 mg/mL.
  • the dosing solution was administered to three mice at 2 mg/kg i.v. via the tail vein and to three further mice at 10 mg/kg p.o. via oral gavage.
  • Blood samples (ca. 20 ⁇ L) were collected at 2, 5, 20 min, 1, 2, 4, 8 and 12 h after i.v. dosing and at 15, 30 min, 1, 2, 4, 8, 12 and 24 h after oral dosing.
  • the blood samples were diluted with 3 volumes of distilled water and stored at ⁇ 80° C. until analysis. The samples were analysed by UPLC-MS/MS (API 5500).
  • Example A exhibited 66% oral bioavailability in male C57 mice, with a terminal half life of 4.9 hours after oral dosing and 4.2 hours after i.v. dosing. No abnormal effects were observed in the mice.
  • the mean whole blood concentration-time profiles of Example A after i.v. and p.o. dosing are shown in FIG. 11 .
  • Example A was dissolved in 5% DMA+10% Solutol+85%(10% HPBCD in saline) to afford a clear dosing solution of 1 mg/mL.
  • the dosing solution was administered to three rats at 2 mg/kg i.v. via the foot dorsal vein and to three further rats at 10 mg/kg p.o. via oral gavage.
  • Blood samples (ca. 150 ⁇ L) were collected at 2, 5, 20 min, 1, 2, 4, 8, 12 and 24 h after i.v. dosing and at 5, 15, 30 min, 1, 2, 4, 8, 12 and 24 h after oral dosing.
  • the blood samples were centrifuged at 4° C. (2000 g, 5 min) within 15 min of sample collection to obtain plasma samples. Plasma samples were stored at ⁇ 80° C. until analysis. The samples were analysed by UPLC-MS/MS (API 4000).
  • Example A exhibited 100% oral bioavailability in male SD rats, with a terminal half life of 9.1 hours after oral dosing and 2.2 hours after i.v. dosing. No abnormal effects were observed in the rats.
  • the mean plasma concentration-time profiles of Example A after i.v. and p.o. dosing are shown in FIG. 12 .
  • a human ADPKD patient-derived (OX161) cell line was used to investigate the effects of PDE4 long form activators on the formation of kidney cysts in vitro and evaluate their potential in the treatment of polycystic kidney diseases.
  • Conditionally immortalised OX161 cystic tubular epithelial cells were generated from human kidneys removed for clinical indications from ADPKD patients with characterised PKD1 (PC1) mutations (Parker, E., Newby, L. J., Sharpe, C. C., Rossetti, S., Streets, A. J., Harris, P. C., O'Hare, M. J., Ong, A. C. M. Kidney Int. 72(2): 157-165, 2007).
  • OX161 cells (50,000 cells/well) were seeded into collagen (Life Technologies; final concentration 1 mg/mL), containing 17 mM NaOH in DMEM, supplemented with 2% (v/v) FBS, 2 mM L-glutamine and 2 mM L-glutamine, 1,000 U penicillin and 1,000 ⁇ g streptomycin (DMEM-2% FBS), on ice.
  • DMEM-2% FBS 2% (v/v) FBS
  • 2 mM L-glutamine and 2 mM L-glutamine 1,000 U penicillin and 1,000 ⁇ g streptomycin
  • Phase-contrast images were obtained every 2 days for 10 days. Per condition, 10 images were taken (in duplicate) and the average cyst area calculated.
  • Example A inhibited in vitro cyst formation in the OX161 cells in a concentration dependent manner.
  • Phase-contrast images were obtained every 2 days for 20 days. Per condition, 10 images were taken (in duplicate) and the average cyst area calculated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
US15/559,875 2015-03-20 2016-03-18 Triazole derivatives and their use as PDE4 activators Active US10385027B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1504763.2 2015-03-20
GBGB1504763.2A GB201504763D0 (en) 2015-03-20 2015-03-20 Compounds and uses
PCT/GB2016/050766 WO2016151300A1 (en) 2015-03-20 2016-03-18 Triazole derivatives and their use as pde4 activators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2016/050766 A-371-Of-International WO2016151300A1 (en) 2015-03-20 2016-03-18 Triazole derivatives and their use as pde4 activators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/508,001 Division US10793531B2 (en) 2015-03-20 2019-07-10 Triazole derivatives and their use as PDE4 activators

Publications (2)

Publication Number Publication Date
US20180057466A1 US20180057466A1 (en) 2018-03-01
US10385027B2 true US10385027B2 (en) 2019-08-20

Family

ID=53052153

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/559,875 Active US10385027B2 (en) 2015-03-20 2016-03-18 Triazole derivatives and their use as PDE4 activators
US16/508,001 Active US10793531B2 (en) 2015-03-20 2019-07-10 Triazole derivatives and their use as PDE4 activators

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/508,001 Active US10793531B2 (en) 2015-03-20 2019-07-10 Triazole derivatives and their use as PDE4 activators

Country Status (5)

Country Link
US (2) US10385027B2 (enExample)
EP (1) EP3271338B1 (enExample)
JP (1) JP6694452B2 (enExample)
GB (1) GB201504763D0 (enExample)
WO (1) WO2016151300A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046660B2 (en) 2016-09-28 2021-06-29 Mironid Limited Compounds and their use as PDE4 activators
US11560373B2 (en) 2018-04-04 2023-01-24 Mironid Limited Compounds and their use as PDE4 activators

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504763D0 (en) 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
GB202102088D0 (en) 2021-02-15 2021-03-31 Mironid Ltd Compounds and their use as pde4 activators
GB202211999D0 (en) 2022-08-17 2022-09-28 Mironid Ltd Compounds and their use as PDE4 activators
GB202212000D0 (en) 2022-08-17 2022-09-28 Mironid Ltd Compounds and their use as PDE4 activators

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936221A1 (en) 1996-09-18 1999-08-18 Lead Chemical Company Ltd. Novel 2,4-dioxopyrrolidine and 2,4-dioxotetrahydrofuran derivatives and medicines containing the same as the active ingredient
WO2004071447A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
US20050137168A1 (en) 2003-12-19 2005-06-23 Gobbi Luca C. Heterocyclyl substituted 1-alkoxy acetic acid amides
WO2007097927A2 (en) 2006-02-15 2007-08-30 Misonix Incorporated Liquid processing and handling apparatus and associated method for use in medical procedures
US20090186900A1 (en) 2006-02-27 2009-07-23 Nigel Vicker Compound
WO2009131956A1 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
US20100144733A1 (en) 2008-04-28 2010-06-10 Institute For Oneworld Health Compounds, compositions and methods comprising heteroaromatic derivatives
US20100222336A1 (en) 2006-08-07 2010-09-02 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
US20100267741A1 (en) 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyrazole Derivatives
WO2010131195A1 (en) 2009-05-12 2010-11-18 Koninklijke Philips Electronics N.V. Phosphodiesterase 4d7 as prostate cancer marker
WO2010131194A1 (en) 2009-05-12 2010-11-18 Koninklijke Philips Electronics N.V. Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
US20120053218A1 (en) 2009-03-18 2012-03-01 Bayer Pharma Aktiengesellschaft Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency
WO2013021044A1 (de) 2011-08-11 2013-02-14 Bayer Intellectual Property Gmbh 1,2,4-triazolyl-substituierte ketoenole
US20130150341A1 (en) 2011-12-08 2013-06-13 Matthias Grauert Novel compounds
US20130184248A1 (en) 2012-01-17 2013-07-18 Boehringer Ingelheim International Gmbh Novel compounds
WO2014150326A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2018060704A1 (en) 2016-09-28 2018-04-05 Mironid Limited Compounds and their use as pde4 activators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004232958A1 (en) * 2003-04-16 2004-11-04 F.-Hoffmann La-Roche Inc. 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
GB201504763D0 (en) 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936221A1 (en) 1996-09-18 1999-08-18 Lead Chemical Company Ltd. Novel 2,4-dioxopyrrolidine and 2,4-dioxotetrahydrofuran derivatives and medicines containing the same as the active ingredient
WO2004071447A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
US20050137168A1 (en) 2003-12-19 2005-06-23 Gobbi Luca C. Heterocyclyl substituted 1-alkoxy acetic acid amides
WO2007097927A2 (en) 2006-02-15 2007-08-30 Misonix Incorporated Liquid processing and handling apparatus and associated method for use in medical procedures
WO2007097927A3 (en) 2006-02-15 2008-01-10 Misonix Inc Liquid processing and handling apparatus and associated method for use in medical procedures
US20090186900A1 (en) 2006-02-27 2009-07-23 Nigel Vicker Compound
US20100222336A1 (en) 2006-08-07 2010-09-02 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
WO2009131956A1 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
US20100144733A1 (en) 2008-04-28 2010-06-10 Institute For Oneworld Health Compounds, compositions and methods comprising heteroaromatic derivatives
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
US20120053218A1 (en) 2009-03-18 2012-03-01 Bayer Pharma Aktiengesellschaft Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency
US20100267741A1 (en) 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyrazole Derivatives
WO2010131194A1 (en) 2009-05-12 2010-11-18 Koninklijke Philips Electronics N.V. Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
WO2010131195A1 (en) 2009-05-12 2010-11-18 Koninklijke Philips Electronics N.V. Phosphodiesterase 4d7 as prostate cancer marker
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
WO2013021044A1 (de) 2011-08-11 2013-02-14 Bayer Intellectual Property Gmbh 1,2,4-triazolyl-substituierte ketoenole
US20140302988A1 (en) 2011-08-11 2014-10-09 Bayer Intellectual Property Gmbh 1,2,4-Triazolyl-Substituted Ketoenols
US20130150341A1 (en) 2011-12-08 2013-06-13 Matthias Grauert Novel compounds
US20130184248A1 (en) 2012-01-17 2013-07-18 Boehringer Ingelheim International Gmbh Novel compounds
WO2014150326A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2018060704A1 (en) 2016-09-28 2018-04-05 Mironid Limited Compounds and their use as pde4 activators

Non-Patent Citations (79)

* Cited by examiner, † Cited by third party
Title
Aandahl et al., Protein kinase a type I antagonist restores immune responses of T cells from HIV-infected patients; The FASEB Journal, vol. 12, Jul. 1, 1998 pp. 855-862.
Agarwal et al., Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase; Nature, vol. 460, Jul. 2, 2009 pp. 98-102.
Ahuja et al., The Adenylate Cyclase Toxins; Critical Reviews in Microbiology, vol. 30, Oct. 19, 2008 pp. 187-196.
Almahariq et al., A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion; Molecular Pharmacology, vol. 83, Jan. 2013 pp. 122-128.
Arturi et al., Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features; Experimental and Clinical Endocrinology & Diabetes, vol. 106, 1998 pp. 234-236.
Azevedo et al., The transcriptome that mediates increased cyclic adenosine monophosphate signaling in PRKAR1A defects and other settings; Endocrine Practice, vol. 17, Jul. 2011 pp. 2-7.
Baljinnyam et al., Epac1 promotes melanoma metastasis via modification of heparan sulfate; Pigment Cell & Melanoma Research, vol. 24, Apr. 19, 2011 pp. 680-687.
Belibi et al., Novel targets for the treatment of autosomal dominant polycystic kidney disease; Expert Opinion on Investigational Drugs, vol. 19, Mar. 2010 pp. 315-328.
Biebermann et al., The First Activating TSH Receptor Mutation in Transmembrane Domain 1 Identified in a Family with Nonautoimmune Hyperthyroidism; The Journal of Clinical Endocrinology & Metabolism, vol. 86. Sep. 1, 2001 pp. 4429-4433.
Bolger et al., Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both be UCR1 and catalytic unit domains; Cellular Signalling, vol. 27, Apr. 2015 pp. 756-769.
Breckler et al., Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications; Cellular Signalling, vol. 23, Aug. 2011 pp. 1257-1266.
Burgin et al., Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety; Nature Biotechnology, vol. 28, Jan. 28, 2010 pp. 63-70.
Calvi et al., The Pth/PTHrP receptor in Jansen's metaphyseal chondrodysplasia; Journal of Endocrinological Investigation, vol. 23, Sep. 2000 pp. 545-554.
Cho et al., CREB and Leukemogenesis; Critical reviews in oncogenesis, vol. 16, 2011 pp. 37-46.
Crans-Vargas et al., Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia; Blood, vol. 99, May, 2002 pp. 2617-9.
Diaz et al., McCune-Albright Syndrome and Disorders Due to Activating Mutations of GNAS1; Journal of Pediatric Endocrinology and Metabolism, vol. 20, Apr. 4, 2011 pp. 853-880.
Duprez et al., Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism; Nature Genetics, vol. 7, Jul. 1994 pp. 396-401.
Francis, et al. A Convenient Synthesis of 3, 5-Disubstituted-1, 2, 4-Triazoles; Tetrahedron Letters, Pergamon, GB, vol. 28, No. 43 Jan. 1, 1987 pp. 5133-5136.
Gattone et al., Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist; Nature Medicine, vol. 9, Oct., 2003 pp. 1323-1326.
Gevers et al., Somatostatin analogues for treatment of polycystic liver disease; Current Opinion in Gastroenterology, vol. 27, May 2011 pp. 294-300.
Gong et al., Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes; American Journal of Physiology-Cell Physiology, vol. 284, May 1, 2003 pp. C1205-1214.
Grange et al., The cAMP-specific Phosphodiesterase PDE4D3 is Regulated by Phosphatidic Acid Binding; Journal of Biological Chemistry, vol. 275, Aug. 9, 2000 pp. 33379-33387.
Gurney et al., Small molecule allosteric modulators of phosphodiesterase 4; Handbook of Experimental Pharmacology, vol. 204, 2011 pp. 167-192.
Henderson et al., The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells; British Journal of Cancer, vol. 110, Mar. 4, 2014 pp. 1278-1287.
Holm et al., Impaired Secretion of IL-10 by T Cells from Patients with Common Variable Immunodeficiency—Involvement of Protein Kinase a Type I; Journal of Immunology, vol. 170, Jun. 1, 2003 pp. 5772-5777.
Horvath et al., A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex; European Journal of Human Genetics, vol. 16, Oct. 2008 pp. 1245-1253.
Horvath et al., A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia; Nature Genetics, vol. 38, Jun. 11, 2006 pp. 794-800.
Horvath et al., Adrenal Hyperplasia and Adenomas Are Associated with Inhibition of Phosphodiesterase 11A in carriers of PDE11A Sequence Variants That Are Frequent in the Population; Cancer Research, vol. 66, Dec. 2006 pp. 11571-11575.
Horvath et al., Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors; Cancer Research, vol. 69, Jul. 2009 pp. 5301-5306.
Horvath et al., Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia; The New England Journal of Medicine, vol. 358, Feb. 2008 pp. 750-752.
Houslay et al., The Multienzyme PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions; Advances in Pharmacology vol. 44, 1998 pp. 225-34.
Houslay, et al., cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signalling; Circulation Research, vol. 100, Apr. 13, 2007 pp. 950-66.
Houslay, et al., Phosphodiesterase-4 as a therapeutic target; Drug Discovery Today, vol. 10, No. 22, Nov. 2005 pp. 1503-1519.
Houslay, M.D., PDE4 cAMP-specific phosphodiesterases; Progress in Nucleic Acid Research and Molecular Thology, vol. 69, May 7, 2001 pp. 249-315.
International Search Report and Written Opinion of International Application No. PCT/GB2016/050766 dated May 13, 2016; 13 pages.
Janssen et al., Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease; Journal Df Hepatology, vol. 52, Mar. 2010 pp. 432-440.
Karles et al., TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5; Journal of Endocrinology, vol. 186, Aug. 2005 pp. 377-385.
Kosugi et al., Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty; Human Molecular Genetics, vol. 4, Feb. 1, 1995 pp. 183-188.
Lania et al., cAMP pathway and pituitary tumorigenesis; Annales d'Endocrinologie, vol. 73, Apr. 2012 pp. 73-75.
Lania et al., G protein mutations in endocrine diseases; European Journal of Endocrinology, vol. 145, Nov. 2001 pp. 543-559.
Latronico et al., A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty; The Journal of Clinical Endocrinology and Metabolism, vol. 80, Aug. 1, 1995 pp. 2490-2494.
Lau et al., Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes; Drug Metabolism and Disposition, vol. 30, Aug. 20, 2002 pp. 1446-1454.
Levy et al., Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment; Current Opinion in Pharmacology, vol. 11, Dec. 2011 pp. 689-697.
Libé et al., Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Camey Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in Cnc as a Modifier of the Phenotype; The Journal of Clinical Endocrinology and Metabolism, vol. 96, Jan. 1, 2011 pp. E208-214.
Libé et al., Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors; Cancer Research, vol. 14, Jun. 2008 pp. 4016-4024.
Lorenz et al., The cAMP/Epac1/Rap1 Pathway in Pancreatic Carcinoma; Pancreas, vol. 37, Jul. 2008 pp. 102-103.
Lugnier, C., Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific herapeutic agents; Pharmacology & Therapeutics, vol. 109, 2006 pp. 366-398.
Ma et al., Mutations of HNF-1? inhibit epithelial morphogenesis through dysregulation of SOCS-3; Proceedings of the National Academy of Sciences of the United States of America, vol. 104, Dec. 18, 2007 pp. 20386-20391.
Mackenzie et al., Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1); British Journal of Pharmacology, vol. 136, Jun. 2002 pp. 421- 433.
Mancusi et al., HNF-1? mutation affects PKD2 and SOCS3 expression causing renal cysts and diabetes in MODY5 Kindred; Journal of Nephrology, vol. 26, Jan. 2013 pp. 207-12.
Mao et al., Thiazolidinediones inhibit MDCK cyst growth through disrupting orientated cell division and apicobasal polarity; American Journal of Physiology-Renal Physiology, vol. 300(6), Jun. 2011 pp. F1375-F1384.
Marchmont et al., A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes; Biochemical Journal, vol. 187, May 1, 1980 pp. 381-92.
Masoum et al., Potential pharmacological interventions in polycystic kidney disease; Drugs, vol. 67, Jan. 1, 2007 pp. 2495-2510.
Masyuk et al., Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate; Gastroenterology, vol. 132, Mar. 2007 pp. 1104-1116.
Meng et al., "An Efficient and Recyclable Heterogeneous Catalytic System for the Synthesis of 1, 2, 4-triazoles using air as the oxidant" RSC Advances: An International Journal to Further Chemical Sciences, vol. 4, No. 17, Jan. 1, 2014 pp. 8612.
Merkle et al., 'Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor; Cellular Signalling, vol. 23, Mar. 2011 pp. 507-515.
Misra et al., Epac1?induced cellular proliferation in prostate cancer cells is mediated by B?Raf/ERK and mTOR signaling cascades; Journal of Cellular Biochemistry, vol. 108, Sep. 1, 2009 pp. 998-1011.
Misra et al., Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: Assembly of a multiprotein signaling complex; Journal of Cellular Biochemistry, vol. 113, 2012 pp. 1488-1500.
Nayjib et al., In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice; The Open Immunology Journal, vol. 170, 2008 pp. 20-24.
Parker et al., Insulin-like growth factor-1 induces hyperproliferation of PKD1 cystic cells via a Ras/Raf dependent signalling pathway; Kidney International, vol. 72(2), Mar. 28, 2007 pp. 157-165.
Persani et al., Induction of Specific Phosphodiesterase Isoforms by Constitutive Activation of the cAMP Pathway in Autonomous Thyroid Adenomas; The Journal of Clinical Endocrinology & Metabolism, vol. 85, Aug. 1, 2000 pp. 2872-2878.
Richter, et al., Dimerization of the Type 4 cAMP-specific Phosphodiesterases is Mediated by the Upstream Conserved Regions (UCRs)*; The Journal of Biological Chemistry, vol. 277, Oct. 25, 2002 pp. 40212-40221.
Shankar et al., The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia; Cancer Cell, vol. 7, Apr., 2005 pp. 351-62.
Strazzabosco et al., polycystic liver diseases: congenital disorders of cholangiocyte signaling; Gastroenterology, vol. 140, Jun. 1, 2011 pp. 1855-1859.
Sun et al., Drug discovery for polycystic kidney disease; Acta Pharmacologica Sinica, vol. 32, Jun. 1, 2011 pp. 305-816.
Sussman et al., Phosphodiesterase 1A Modulates Cystogenesis in Zebrafish; Journal of the American Society of Nephrology, vol. 25, Oct., 2014 pp. 2222-2230.
Takiar et al., Polycystic kidney disease: pathogenesis and potential therapies; Biochimica et Biophysica Acta, vol. 1812, Oct. 2011 pp. 1337-1343.
Thompson et al., G protein-coupled receptors disrupted in human genetic disease; Methods in Molecular Biology, vol. 448, Jan. 1, 2008 pp. 109-137.
Thompson et al., Multiple cyclic nucleotide phosphodiesterase activities from rat brain; Biochemistry, vol. 10, Jan. 19, 1971 pp. 311-316.
Torres et al., Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease; Nature Medicine, vol. 10, Apr. 2004 pp. 363-364.
Tritos et al., Advances in medical therapies for Cushing's syndrome; Discovery Medicine, vol. 13, Feb. 2012 pp. 171-179.
UK Search Report for GB Application No. 1504763.2 dated Dec. 15, 2015; 5 pages.
United Kingdom Search Report issued in GB application No. GB1805527.7, dated Nov. 21, 2018; 2 pages.
Vezzosi et al., Phosphodiesterases in endocrine physiology and disease; European Journal of Endocrinology, vol. 165, Aug. 2011 pp. 177-188.
Wade et al. Synthesis of the Triazolo[5,1-a][2,4] benzodiazepine Ring System; The Journal of Organic Chemistry, vol. 44, No. 1, Jan. 1, 1979 pp. 84-88.
Wallace, D., Cyclic AMP-mediated cyst expansion; Biochimica et Biophysica Acta, vol. 1812, Oct. 2011 pp. 1291-1300.
Wang et al., UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy; Cellular Signalling, vol. 27, May 2015 908-922.
Weinstein et al., Minireview: GNAS: Normal and Abnormal Functions; Endocrinology, vol. 145, Dec. 1, 2004 pp. 5459-5464.
Yamaguchi et al., cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellulan signal-regulated kinase pathway; Kidney International, vol. 57, Apr. 2000 pp. 1460-1471.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046660B2 (en) 2016-09-28 2021-06-29 Mironid Limited Compounds and their use as PDE4 activators
US11560373B2 (en) 2018-04-04 2023-01-24 Mironid Limited Compounds and their use as PDE4 activators

Also Published As

Publication number Publication date
JP2018515594A (ja) 2018-06-14
US20200002296A1 (en) 2020-01-02
GB201504763D0 (en) 2015-05-06
JP6694452B2 (ja) 2020-05-13
WO2016151300A1 (en) 2016-09-29
EP3271338A1 (en) 2018-01-24
EP3271338B1 (en) 2019-09-04
US20180057466A1 (en) 2018-03-01
US10793531B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
US10793531B2 (en) Triazole derivatives and their use as PDE4 activators
US11046660B2 (en) Compounds and their use as PDE4 activators
US11560373B2 (en) Compounds and their use as PDE4 activators
KR102742235B1 (ko) 라이실 옥시다제의 할로알릴아민 인돌 및 아자인돌 유도체 억제제 및 이의 용도
CN102271679A (zh) 包含磺酰胺的化合物及其用途
Allas et al. Clinical perspectives for ghrelin-derived therapeutic products
US20170275249A1 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
US9403833B2 (en) Carboxamide derivatives
JP2013510191A (ja) Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
JP2017520588A (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
JP2011516486A (ja) 骨質量疾患の診断、予防、及び治療方法
TW200826927A (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP2008545801A (ja) スルホンアミド化合物およびその使用
US20190016680A1 (en) Mast-cell modulators and uses thereof
CA2579242A1 (en) Sulfonamides and uses thereof
CN1518445A (zh) 性功能障碍的治疗
US6949564B2 (en) NPY-5 antagonists
EP4572757A1 (en) Compounds and their use as pde4 activators
JP2006511529A (ja) Ｎｐｙ−５アンタゴニストとしての５−アミノフェナンスリジン誘導体
WO2024038128A1 (en) Compounds and their use as pde4 activators

Legal Events

Date Code Title Description
AS Assignment

Owner name: MIRONID LIMITED, SCOTLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADAM, JULIA;REEL/FRAME:043637/0478

Effective date: 20170913

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4